Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. cut its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 28,802 shares of the company’s stock after selling 1,775 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.07% of Voyager Therapeutics worth $243,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Armistice Capital LLC raised its stake in shares of Voyager Therapeutics by 15.3% during the 3rd quarter. Armistice Capital LLC now owns 4,178,000 shares of the company’s stock worth $32,380,000 after buying an additional 554,000 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Voyager Therapeutics by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock valued at $1,495,000 after acquiring an additional 1,455 shares in the last quarter. TD Asset Management Inc raised its position in Voyager Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 133,502 shares of the company’s stock worth $1,035,000 after acquiring an additional 66,751 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at about $980,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at approximately $887,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VYGR has been the topic of a number of analyst reports. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. HC Wainwright assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective for the company. Guggenheim initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price on the stock. Citigroup began coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 price target for the company. Finally, Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $14.00 in a research note on Tuesday, January 2nd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Voyager Therapeutics Stock Performance

VYGR opened at $7.65 on Wednesday. Voyager Therapeutics, Inc. has a 1 year low of $6.06 and a 1 year high of $14.34. The company’s 50 day simple moving average is $8.79 and its 200 day simple moving average is $7.97. The stock has a market capitalization of $415.40 million, a PE ratio of 2.48 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. As a group, sell-side analysts expect that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.